Keros Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Keros Therapeutics has a total shareholder equity of $703.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $742.8M and $39.2M respectively. Keros Therapeutics's EBIT is $46.5M making its interest coverage ratio -1.7. It has cash and short-term investments of $693.5M.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -1.7x |
| Cash | US$693.47m |
| Equity | US$703.58m |
| Total liabilities | US$39.20m |
| Total assets | US$742.78m |
Recent financial health updates
We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth
Nov 20
Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation
Aug 07We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
Sep 24We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth
Jun 10Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Dec 25Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Sep 08Recent updates
Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%
Nov 18Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path
Aug 21Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being
May 29Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point
May 14Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified
May 09Keros Therapeutics: Losing Its Lead Drug Is Bad Medicine
Mar 13Keros Therapeutics: How To Respond To Today's Major Safety Setback And Selloff
Dec 12We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth
Nov 20Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation
Aug 07Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers
Jun 10Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?
Apr 23We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
Sep 24We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth
Jun 10Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Dec 25Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Sep 08Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07
Aug 04Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Apr 29We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
Jan 24Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Oct 10We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
May 05Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?
Mar 13We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate
Jan 19Financial Position Analysis
Short Term Liabilities: KROS's short term assets ($719.3M) exceed its short term liabilities ($24.1M).
Long Term Liabilities: KROS's short term assets ($719.3M) exceed its long term liabilities ($15.1M).
Debt to Equity History and Analysis
Debt Level: KROS is debt free.
Reducing Debt: KROS had no debt 5 years ago.
Debt Coverage: KROS has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: KROS has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/13 02:36 |
| End of Day Share Price | 2026/01/12 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Keros Therapeutics, Inc. is covered by 18 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Zemansky | BofA Global Research |
| Corinne Johnson | Goldman Sachs |
| Andrew Fein | H.C. Wainwright & Co. |